• Revolution Medicines’ NDA for daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma was accepted for FDA review.
• Application is backed by Phase 3 RASolute 302 results showing improved overall survival and progression-free survival versus chemotherapy.
• Drug was selected for the FDA Commissioner’s National Priority Voucher pilot, which can speed review timelines.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607221605PRIMZONEFULLFEED9766568) on July 22, 2026, and is solely responsible for the information contained therein.